News

Most Lymphomatoid Papulosis Has Benign Course


 

FROM THE SDEF LAS VEGAS DERMATOLOGY SEMINAR

Dr. Gibson stated that he had no relevant financial disclosures or conflicts of interest. SDEF and this news organization are owned by Elsevier.

Pages

Recommended Reading

Severe Comorbidity Doubles Death Risk in Multiple Myeloma
MDedge Hematology and Oncology
NICE Expands Chemotherapy Options with Rituximab
MDedge Hematology and Oncology
PBSC Transplants from Unrelated Donors Show No Survival Advantage
MDedge Hematology and Oncology
Stem Cell Transplant: Physical, Mental Health Burdens Persist
MDedge Hematology and Oncology
Carfilzomib Analyses Provide New Insights in Multiple Myeloma
MDedge Hematology and Oncology
BTK Inhibitor Draws High Response Rate in CLL
MDedge Hematology and Oncology
Observation Suffices After Rituximab in Low-Burden Follicular Lymphoma
MDedge Hematology and Oncology
Chemotherapy Alone Bests Radiation for Nonbulky Hodgkin's Lymphoma
MDedge Hematology and Oncology
Obinutuzumab Equals Rituximab in Relapsed Indolent NHL
MDedge Hematology and Oncology
HL drug demonstrates activity and toxicity
MDedge Hematology and Oncology